$KALV
KalVista Pharmaceuticals, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021047480 Filed on September 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.847M $3.280M
YoY Change 78.26% 0.92%
% of Gross Profit
Research & Development $13.67M $11.17M
YoY Change 22.37% 15.27%
% of Gross Profit
Depreciation & Amortization $132.0K $128.0K
YoY Change 3.13% 5.79%
% of Gross Profit
Operating Expenses $19.52M $14.44M
YoY Change 35.15% 11.65%
Operating Profit -$19.52M
YoY Change
Interest Expense $223.0K $700.0K
YoY Change -68.14% 400.0%
% of Operating Profit
Other Income/Expense, Net $3.184M $2.930M
YoY Change 8.67% 40.19%
Pretax Income -$16.11M -$10.81M
YoY Change 49.02% 47.28%
Income Tax
% Of Pretax Income
Net Earnings -$16.11M -$10.81M
YoY Change 48.96% 47.37%
Net Earnings / Revenue
Basic Earnings Per Share -$0.66
Diluted Earnings Per Share -$659.4K -$605.6K
COMMON SHARES
Basic Shares Outstanding 24.44M
Diluted Shares Outstanding 24.43M

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $230.6M $64.30M
YoY Change 258.68% -35.93%
Cash & Equivalents $48.34M $18.01M
Short-Term Investments $182.3M $46.30M
Other Short-Term Assets $5.538M $3.300M
YoY Change 67.82% 22.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $249.8M $80.20M
YoY Change 211.45% -30.69%
LONG-TERM ASSETS
Property, Plant & Equipment $9.151M $3.500M
YoY Change 161.46% 55.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K
YoY Change 0.0% 15.61%
Total Long-Term Assets $9.351M $3.702M
YoY Change 152.59% -11.12%
TOTAL ASSETS
Total Short-Term Assets $249.8M $80.20M
Total Long-Term Assets $9.351M $3.702M
Total Assets $259.1M $83.90M
YoY Change 208.85% -30.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.448M $1.800M
YoY Change -19.56% -41.99%
Accrued Expenses $5.876M $6.700M
YoY Change -12.3% 57.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.229M $8.500M
YoY Change -3.19% -39.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.474M $1.000M
YoY Change 547.4% -75.61%
Total Long-Term Liabilities $6.474M $1.000M
YoY Change 547.4% -75.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.229M $8.500M
Total Long-Term Liabilities $6.474M $1.000M
Total Liabilities $14.70M $9.500M
YoY Change 54.77% -47.27%
SHAREHOLDERS EQUITY
Retained Earnings -$183.9M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $244.4M $74.44M
YoY Change
Total Liabilities & Shareholders Equity $259.1M $83.90M
YoY Change 208.86% -30.02%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$16.11M -$10.81M
YoY Change 48.96% 47.37%
Depreciation, Depletion And Amortization $132.0K $128.0K
YoY Change 3.13% 5.79%
Cash From Operating Activities -$17.74M -$3.588M
YoY Change 394.29% -68.18%
INVESTING ACTIVITIES
Capital Expenditures $287.0K $22.00K
YoY Change 1204.55% -77.55%
Acquisitions
YoY Change
Other Investing Activities $15.17M $5.540M
YoY Change 173.79% -487.41%
Cash From Investing Activities $14.88M $5.513M
YoY Change 169.93% -460.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 608.0K 46.00K
YoY Change 1221.74% -99.6%
NET CHANGE
Cash From Operating Activities -17.74M -3.588M
Cash From Investing Activities 14.88M 5.513M
Cash From Financing Activities 608.0K 46.00K
Net Change In Cash -2.249M 2.225M
YoY Change -201.08% -217.17%
FREE CASH FLOW
Cash From Operating Activities -$17.74M -$3.588M
Capital Expenditures $287.0K $22.00K
Free Cash Flow -$18.02M -$3.610M
YoY Change 399.22% -68.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
19516000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-129000
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-23000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
257193000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
608000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2795000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16109000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
46000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10814000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
338000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2020Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
70000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-16109000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-10814000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
132000
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
128000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2795000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1188000
CY2021Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-23000
CY2020Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
70000
CY2021Q3 kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
22000
CY2020Q3 kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
8000
CY2021Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
753000
CY2020Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
68000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-14000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
432000
CY2021Q3 kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
3211000
CY2020Q3 kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-4462000
CY2021Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
625000
CY2020Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1301000
CY2021Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-528000
CY2020Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
35000
CY2021Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1001000
CY2020Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
538000
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17735000
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3588000
CY2021Q3 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
19036000
CY2020Q3 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
9807000
CY2021Q3 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
34204000
CY2020Q3 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
15342000
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000
CY2020Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14881000
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5513000
CY2021Q3 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
608000
CY2020Q3 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
46000
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
608000
CY2020Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46000
CY2021Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3000
CY2020Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
254000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2249000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2225000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15789000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48343000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18014000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183900000
CY2021Q3 kalv Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
230600000
CY2021Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4178000
CY2021Q3 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
186466000
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
2985000
CY2021Q2 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
201322000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
182593000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
36000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
341000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
182288000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
198536000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
62000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
261000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
198337000
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
126975000
CY2021Q3 kalv Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
34419000
CY2021Q3 kalv Available For Sale Securities Debt Maturities After Two Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughFourYearsFairValue
20894000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
182288000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1579000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3507000
CY2021Q3 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
3387000
CY2021Q2 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
2476000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
730000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
557000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
180000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
390000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5876000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6930000
CY2021Q3 kalv Contractual Obligation Remaining Commitment Including Cancellation Provisions
ContractualObligationRemainingCommitmentIncludingCancellationProvisions
29100000
CY2021Q3 kalv Amount Associated With Indemnification
AmountAssociatedWithIndemnification
0
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1105000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1419000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1292000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1322000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1353000
CY2021Q3 kalv Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
3336000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9827000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2448000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7379000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
905000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6474000

Files In Submission

Name View Source Status
0001564590-21-047480-index-headers.html Edgar Link pending
0001564590-21-047480-index.html Edgar Link pending
0001564590-21-047480.txt Edgar Link pending
0001564590-21-047480-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kalv-10q_20210731.htm Edgar Link pending
kalv-10q_20210731_htm.xml Edgar Link completed
kalv-20210731.xsd Edgar Link pending
kalv-20210731_cal.xml Edgar Link unprocessable
kalv-20210731_def.xml Edgar Link unprocessable
kalv-20210731_lab.xml Edgar Link unprocessable
kalv-20210731_pre.xml Edgar Link unprocessable
kalv-ex311_8.htm Edgar Link pending
kalv-ex312_6.htm Edgar Link pending
kalv-ex321_7.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending